Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gliatech

This article was originally published in The Gray Sheet

Executive Summary

Anti-adhesion gel maker raises $15-30 mil. in a staged equity financing from Paul Capital Partners. The funds include an up-front payment of $5 mil. to be used for preparing a submission to FDA for commercial re-launch of Adcon-L anti-adhesive gel in the U.S. The company discontinued distribution of the product, approved in June 1998 to inhibit scarring following lumbar surgery, in January 2001 following a recall initiated by the product's supplier (1"The Gray Sheet" Jan. 15, 2001, p. 23). An additional $2.5 mil. will be placed following the re-launch of the product outside the U.S., slated for June 2001. Another $7.5 mil. will be paid following the product's re-launch in the U.S. The agreement includes an option for a further investment of $15 mil. Under the terms of the deal, Paul Capital Partners will receive either roughly 2.5% of net sales of the Adcon product line, or minimum annual royalty payments beginning in 2003 at a rate of $1.6 mil. a year, depending on which amount is greater. The initial $5 mil. cash infusion leaves Gliatech with about $13 mil. in cash and short-term investments. The firm reported no revenues in the first quarter (ended March 31) of 2001
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT014864

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel